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Introduction {#sec005}
============

According to the International Continence Society (ICS), the most common types of urinary incontinence are urgency urinary incontinence (UUI), stress urinary incontinence (SUI), and mixed urinary incontinence (MUI). UUI is a common symptom of overactive bladder syndrome (OAB) which is defined by ICS as urinary urgency with or without incontinence, often accompanied by frequency (typically defined in clinical trials as ≥ 8 micturitions per 24 hours) and nocturia (defined as ≥ 1 micturition interrupting sleep) in the absence of urinary tract infection or other obvious pathology \[[@pone.0235961.ref001], [@pone.0235961.ref002]\]. OAB affects a significant proportion of the United States (US) population and thus represents a major public health burden \[[@pone.0235961.ref003], [@pone.0235961.ref004]\]. In one study, OAB was found to affect 42.2 million adults in the US population with an estimated disease-specific total societal cost of \$24.9 billion \[[@pone.0235961.ref005]\]. Based on the forecasted increases in the prevalence of OAB in the US population, the total national costs in 2020 are projected to be \$82.6 billion \[[@pone.0235961.ref006]\].

Numerous studies have assessed the prevalence of OAB in developed countries, with the National Overactive Bladder Evaluation (NOBLE) and the epidemiology of lower urinary tract symptoms (EpiLUTS) studies being the most well-known \[[@pone.0235961.ref007], [@pone.0235961.ref008]\]. NOBLE study reported the US prevalence of OAB to be 16.5%; 10.4% of OAB without UUI and 6.1% of OAB with UUI. Contrary to the popular belief, the prevalence of overall OAB was similar in women and men (16.9 vs. 16.0%) \[[@pone.0235961.ref008]\]. Similar estimates have been reported in the European population, with an OAB prevalence of 15.6% in men and 17.4% in women \[[@pone.0235961.ref009]\]. In the US-based EpiLUTS study, the prevalence of OAB depended on how OAB was defined. When symptoms were defined as "sometimes", the overall prevalence was 35.6%. With a more restrictive definition of "often", the prevalence decreased to 24.7%. Regardless of the definition, the prevalence increased with increasing age \[[@pone.0235961.ref007]\].

Multiple medical specialties including primary care physicians, gynecologists, urologists and subspecialists in pelvic floor disorders manage OAB in different capacities. The treatment of OAB commences with conservative therapies such as biofeedback and behavioral therapy that are often combined with second-line pharmacological treatment such as antimuscarinics and beta-3 agonists. Although behavioral and pharmacological therapies remain the first- and second-line treatments respectively for OAB, decreased efficacy and poor compliance have been reported \[[@pone.0235961.ref010]--[@pone.0235961.ref014]\]. A diagnosis of refractory OAB is considered when a patient has not adequately responded to lifestyle modifications, bladder training and pelvic floor therapy administered for a duration of at least 8--12 weeks, and treatment with at least one anti-muscarinic therapy for a period of at least 4--8 weeks \[[@pone.0235961.ref015]\]. In such patients, intra-detrusor injection of Onabotulinum toxin A, posterior tibial nerve stimulation (PTNS) and sacral neuromodulation (SNM) are the available third-line therapies \[[@pone.0235961.ref016]\].

SNM is a minimally invasive fully reversible therapy that was approved by the US Food and Drug Administration (FDA) in 1997 for refractory OAB. SNM is defined as a technique that electrically stimulates the third sacral spinal nerve root to modulate a neural pathway with the aim of treating bladder and/or bowel dysfunction \[[@pone.0235961.ref017]\]. The exact mechanism of action of SNM is unknown, however, it is believed to correct the balance between the peripheral sacral nerves and the central nervous system by stimulating the afferent sensory fibers of the pelvic and pudendal nerves \[[@pone.0235961.ref018]\]. Following its approval, SNM has been increasingly utilized for OAB, and the evidence base for its medium to long-term (3 plus years) safety and efficacy is gradually building up \[[@pone.0235961.ref019]--[@pone.0235961.ref026]\]. However, the majority of the existing literature has been funded by the SNM device manufacturer \[[@pone.0235961.ref021], [@pone.0235961.ref024]--[@pone.0235961.ref029]\]. We therefore investigated the medium-term efficacy and safety of SNM along with the predictive factors for its success in patients with refractory OAB treated at a single institution with no funding from the manufacturer.

Methods {#sec006}
=======

Study design and patient population {#sec007}
-----------------------------------

The present study was approved by the Allen College Institutional Review Board (ACIRB) and was conducted according to the guidelines laid down in the Declaration of Helsinki. Since there was no direct patient contact in this study, the need for written informed consent was waived by ACIRB. This study involved collection of existing data from patient records in such a manner that subjects cannot be identified, directly or through identifiers linked to the subjects. All patient records/information was de-identified prior to analysis.

We retrospectively examined a consecutive case series of 66 patients undergoing SNM for refractory OAB at our institution between July 2009 and July 2018. A consecutive case series of patients was chosen to avoid non-response and minimize the probability of selection bias. The inclusion criteria were: age\> = 18 years, refractory OAB and a negative urinalysis. Refractory OAB was defined as symptoms of OAB and failure to respond to behavioral modifications and at least two oral pharmacologic agents. Patients with pre-existing neurological conditions affecting urinary function (eg, multiple sclerosis, myasthenia gravis, spinal cord injury, and Parkinson disease), history of pelvic radiation, and prior SNM performed for other indications such as urinary retention or fecal incontinence were excluded. Electronic medical records were reviewed to collect demographic and clinical characteristics, the presence of concomitant conditions (such as voiding symptoms, symptoms of SUI, pelvic organ prolapse \[cystocele, enterocele, rectocele, uterine prolapse and vaginal vault prolapse\], recurrent urinary tract infection \[UTI\], fecal incontinence) as well as the outcomes data.

SNM {#sec008}
---

SNM was performed in two stages such that all patients underwent a test period (percutaneous nerve evaluation \[PNE\] or tined-lead evaluation \[TLE\]) followed by a permanent InterStim II device (Medtronic Inc, Minneapolis, Minn) implantation, which was indicated only if there was a \> = 50% improvement in any of the symptoms (frequency, urgency, and/or UUI). During stage 1, a test electrode (TLE) was placed percutaneously either uni- or bilaterally into the sacral foramen S3 (S2--S4) under general anesthesia or analgesic sedation without muscle relaxation, while PNE was conducted in-office under local anesthesia. A positive response to the test phase was defined as a \> = 50% improvement in bladder symptoms (i.e. a drop in the number of urgency, frequency or UUI episodes by half or more), and positive responders were offered a permanent implant. During stage 2, a battery-powered implantable pulse generator (IPG) was positioned in the fatty tissue of the gluteal region on the side of the electrode and connected to the test electrode under general anesthesia or analgesic sedation \[[@pone.0235961.ref030]\].

Statistical analysis {#sec009}
--------------------

The primary outcome was "success" defined as \> = 50% improvement in any clinical parameter at the last follow-up based on the subjective assessment of patient's response by the physician as mentioned in the clinical note. In other words, success was considered if the number of urgency, frequency or UUI episodes dropped by half or more, as assessed by the physician based on patient's response. Patients also completed a global response assessment (GRA) which assessed patients' perception of overall improvement in bladder symptoms on a 5-point Likert-type scale (much worse, somewhat worse, same, somewhat better, much better). The secondary outcomes were number of pads used in 24 hours, post-operative complications and re-operation (revision and explantation) rates. The following complications were evaluated: pain, lead migration, skin erosion, seroma, hematoma, wound dehiscence, cellulitis, deep wound infection, abscess and device malfunction. The length of follow-up was calculated as the time duration between the date of permanent IPG implant and the most recent date that subjects completed follow-up.

Categorical data was summarized using frequency and percentage whereas continuous/count data using mean and standard deviation or median and range. A paired Student-t-test was used to compare the number of pads used per 24 hours at baseline and last follow-up. Logistic regression was performed to identify factors predicting the success of SNM at the last available follow-up. Owing to the retrospective nature of this study, no formal sample size calculations were conducted. All data were analyzed using IBM SPSS version 23.0 (IBM, Armonk, NY, USA). A difference was considered to be statistically significant if the p value was less than or equal to 0.05.

Results {#sec010}
=======

66 patients (all females) with a median age of 62.7 years (range 28.2--93.6 years) met the inclusion criteria. Patients' baseline characteristics are shown in [Table 1](#pone.0235961.t001){ref-type="table"}. Of a total of 66 patients, 55 (83.3%) had a successful test phase and underwent permanent implantation. As a result, the final analysis included 55 patients. The median time between the test and definitive implant was 35 days (range 11--80 days). The median time to follow-up was 32 months (range 3.2--105.1 months). At the last follow-up, SNM was considered successful in 41/55 (74.5%) patients based on the subjective assessment of patient's response by the physician. The mean number of pads used in 24 hours decreased significantly from 3.5 preoperatively to 1.2 at last follow-up (p\<0.001). Patients' assessment of their symptoms using GRA at the last visit were as follows: 3 (5.5%) "somewhat worse", 12 (21.8%) "same", 24 (43.6%) "somewhat better", and 16 (29.1%) "much better", indicating that 40/55 (72.7%) patients experienced improvement in bladder symptoms from their own perspective, which is consistent with an objective success rate of 74.5% reported above. None of the evaluated factors were identified as predictors of SNM success at the last follow-up visit, as shown in [Table 2](#pone.0235961.t002){ref-type="table"}. Similarly, no factor was found to be associated with the occurrence of revision and explantation.

10.1371/journal.pone.0235961.t001

###### Baseline patient characteristics (N = 66).

![](pone.0235961.t001){#pone.0235961.t001g}

  -------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------ ---------------------- ------------
  **Characteristic**                                                                                                   **Categories**                                         **Number (Percent)**   
  Race                                                                                                                 Caucasian                                              60 (90.9)              
                                                                                                                       African American                                       6 (9.1)                
  Menopausal status                                                                                                    Pre-menopausal                                         8 (12.1)               
                                                                                                                       Post-menopausal                                        58 (87.9)              
  Primary SNM indication                                                                                               OAB dry                                                3 (4.5)                
                                                                                                                       OAB wet                                                63 (95.5)              
  *with UUI*[\*](#t001fn002){ref-type="table-fn"}*with urgency predominant MUI*[\*](#t001fn002){ref-type="table-fn"}   *28 (42*.*5)*                                                                 
  *35 (53)*                                                                                                                                                                                          
  Concomitant conditions                                                                                               Symptoms of SUI[\*](#t001fn002){ref-type="table-fn"}   35 (53)                
                                                                                                                       Pelvic organ prolapse                                  16 (24.2)              
                                                                                                                       Recurrent UTI                                          11 (16.7)              
                                                                                                                       Voiding symptoms                                       51 (77.3)              
                                                                                                                       Fecal incontinence                                     7 (10.6)               
                                                                                                                       Diabetes                                               19 (28.8)              
                                                                                                                       Chronic pelvic or back pain                            35 (53)                
  Prior treatment                                                                                                      Behavioral therapy                                     66 (100)               
                                                                                                                       Anticholinergics                                       66 (100)               
                                                                                                                       Botox                                                  5 (7.6)                
  SNM device                                                                                                           Percutaneous nerve evaluation                          62 (93.9)              
                                                                                                                       Tined-lead evaluation                                  4 (6.1)                
  **Characteristic**                                                                                                   **Mean**                                               **Median**             **Range**
  Age at baseline (years)                                                                                              62.5                                                   62.7                   28.2--93.6
  BMI (kg/m^2^) at baseline                                                                                            34.6                                                   34                     18--54
  Parity                                                                                                               2.7                                                    3.0                    0--6
  Symptom duration at baseline (months)                                                                                51.1                                                   36.0                   12--180
  Pads used in 24 hours at baseline                                                                                    3.5                                                    3.0                    0--30
  -------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------ ---------------------- ------------

BMI = Body mass index; MUI = Mixed urinary incontinence; OAB = Overactive bladder syndrome; SNM = Sacral neuromodulation; SUI = Stress urinary incontinence; UTI = Urinary tract infection; UUI = Urge urinary incontinence

\*UUI was defined as the complaint of involuntary loss of urine associated with urgency; SUI was defined as the complaint of involuntary loss of urine on effort or physical exertion or on sneezing or coughing; MUI was defined as the complaint of involuntary loss of urine associated with urgency and with exertion, effort, sneezing, or coughing (i.e., UUI and SUI).

10.1371/journal.pone.0235961.t002

###### Univariate analysis of factors predicting success of SNM (N = 55).

![](pone.0235961.t002){#pone.0235961.t002g}

  Variables                                             OR      95% CI       P value
  ----------------------------------------------------- ------- ------------ ---------
  Age (continuous)                                      0.99    0.95--1.05   0.82
  BMI (continuous)                                      1.06    0.97--1.2    0.21
  Parity (continuous)                                   1.67    0.86--3.2    0.13
  Pads used in 24 hours at baseline (continuous)        0.97    0.85--1.1    0.70
  Symptom duration in months at baseline (continuous)   0.99    0.98--1.02   0.89
  Duration of test period (continuous)                  1.004   0.99--1.01   0.44
  Menopausal status                                                          
   Pre-menopausal (reference)                                                
   Post-menopausal                                      0.45    0.05--4.1    0.48
  Concomitant voiding symptoms                                               
   No (reference)                                                            
   Yes                                                  0.97    0.22--4.2    0.97
  Concomitant symptoms of SUI                                                
   No (reference)                                                            
   Yes                                                  0.64    0.18--2.3    0.49
  Concomitant recurrent UTI                                                  
   No (reference)                                                            
   Yes                                                  0.89    0.20--3.8    0.88
  Concomitant pelvic organ prolapse                                          
   No (reference)                                                            
   Yes                                                  6.1     0.71--51.2   0.09
  Concomitant fecal incontinence                                             
   No (reference)                                                            
   Yes                                                  0.29    0.05--1.6    0.16
  Concomitant diabetes                                                       
   No (reference)                                                            
   Yes                                                  1.9     0.47--8.3    0.35
  Concomitant chronic pelvic or back pain                                    
   No (reference)                                                            
   Yes                                                  0.68    0.19--2.4    0.55

BMI = Body mass index; CI = Confidence interval; OR = Odds ratio; SNM = Sacral neuromodulation; SUI = Stress urinary incontinence; UTI = Urinary tract infection

Only 8/55 (14.5%) patients experienced complications during the follow-up period such that three patients had pain, two had lead migration, one had IPG migration, one had infection/wound dehiscence, and one had device malfunction. A total of 10 (18.2%) revision surgeries were performed after a median duration of 21.9 months (range 1--77 months) from the date of permanent implant. The reasons for revisions were complications (n = 5) and end of battery life (n = 5). When end of battery life was the reason, the IPG was replaced after a median duration of 57 months (range 16--77 months) from the date of permanent implant.

Device was explanted in 15/55 (27.3%) patients after a median duration of 24 months (range 1--71 months) from the date of permanent implant. The reasons for explantation were decreased device efficacy (n = 5), patient undergoing magnetic resonance imaging (MRI, n = 4), pain (n = 3), end of battery life (n = 2), and infection (n = 1). None of these 15 patients got re-implanted. The 5 patients with decreased device efficacy were considered therapeutic failures and underwent explantation after a median of 24 months (range 11--29 months) from the date of permanent implant.

Discussion {#sec011}
==========

Our study, which adds to the growing evidence base on the medium-term safety and efficacy of SNM in refractory OAB, showed a success rate of 75% after a median follow-up of \~3 years. Previous studies have also evaluated the outcomes of SNM in OAB, however, these studies differ from each other with respect to the underlying sample size, data collection methodology and the length of follow-up, thereby reporting varied SNM success rates. For instance, a retrospective study by Ismail et al. conducted in 34 patients with idiopathic OAB reported a success rate of 63% after a median follow-up of 9.7 years. Additionally, 47% patients underwent revision surgeries mainly for end of battery life/device dysfunction \[[@pone.0235961.ref020]\]. This relatively lower success rate and higher revision rate reported by Ismail et al. could be a function of a long follow-up period. Another retrospective cohort study by Singh et al. in 65 refractory OAB patients reported a success rate of 91% and a re-operation rate of 1.5% with SNM at the end of 6 months. The higher improvement rate in the study by Singh et al. could be attributed to a shorter follow-up period as well as not using objective measurement such as voiding diary or questionnaires to define the primary outcome \[[@pone.0235961.ref031]\]. Siegel at al., in their prospective study of 272 patients undergoing SNM for refractory OAB, reported a 5-year success rate of 82% along with a sustained improvement in patient quality of life. The authors also reported a mean reduction of 2.0 and 5.4 leaks per day in patients with UUI and those with urgency-frequency respectively \[[@pone.0235961.ref021]\]. Finally, a retrospective study by Al-zahrani et al. reported a success rate of 84.8% for urgency incontinence over a mean follow-up of 4.2 years \[[@pone.0235961.ref019]\]. The success rate of 75% reported in our study after a median follow-up of approximately 3 years is broadly consistent with the findings reported by other studies as described above.

We also investigated several potentially predictive factors of SNM success including voiding symptoms, symptoms of SUI, pelvic organ prolapse, diabetes, fecal incontinence and patients demographics (such as age, race and BMI), but did not find any factor to be significantly associated with SNM success. This could possibly be because of a small sample size of our study. The existing literature on the factors associated with SNM outcomes is mixed and inconclusive probably because of the differences in patient populations and types of factors evaluated across studies. Ismail et al. \[[@pone.0235961.ref020]\] and Starkman et al. \[[@pone.0235961.ref032]\] did not find any significant predictors of SNM success from amongst age, symptom duration, baseline symptom severity, presence of concomitant conditions and urodynamic parameters. On the other hand, two studies have reported age under 55 years to be significantly associated with a higher cure rate \[[@pone.0235961.ref033], [@pone.0235961.ref034]\]. While one study found SNM to be more successful in patients with more severe incontinence \[[@pone.0235961.ref022]\], the other reported that SNM is equally effective in treating both less severe and more severely affected groups \[[@pone.0235961.ref028]\]. Furthermore, one study found increasing BMI to be associated with a lower likelihood of success with SNM \[[@pone.0235961.ref035]\]. There is no general consensus on the factors associated with a greater probability of SNM success, and future studies with a prospective design and large sample sizes are needed to further investigate these associations.

We had a relatively low complication rate of 14.5% as compared to a rate of 30%--40% within 5 years of permanent implantation, as reported in the literature \[[@pone.0235961.ref016]\]. In our study, one patient had wound infection leading to dehiscence which was managed by debridement and then revision and explantation at a later date. As for any surgical procedure, strict adherence to sterile technique and emphasis on post-operative discharge instructions help decrease the infection and complication rate. Approximately, one quarter of our patients underwent explantation after a median duration of 2 years. The two main reasons for explantation were the need for MRI and decreased efficacy of the device with time. These findings should help clinicians counsel their patients about the medium-term safety and success of SNM. Moreover, our findings also demonstrate the need for an MRI-safe device in the future. In September 2019, the FDA approved a rechargeable SNM device (Axonics r-SNM System^™^, Irvine, CA) with a conditional safety for 1.5 Tesla full body MRI and 3 Tesla head MRI \[[@pone.0235961.ref036]\]. This new MRI-compatible device is expected to enable more OAB patients to choose SNM as their preferred treatment option.

We had a relatively high re-operation (revision and explantation combined) rate of 45% (18% revision rate and 27% explantation rate). We believe that the high rate of re-operation observed in our study is due to the medium-term follow up of \~3 years. The most common reasons for re-operation were end of battery life (n = 7), complications (n = 5), decreased device efficacy (n = 5) and the need for MRI (n = 4). It is important to note that the median time for explantation due to decreased device efficacy was 24 months. This finding should help clinicians counsel their patients about a potential drop in device efficacy after approximately 2 years of use.

OAB is a challenging condition to treat. Most patients stop using antimuscarinics within 6 months and only 20% continue after a year \[[@pone.0235961.ref037]\]. The published placebo-controlled drug trials in subjects with OAB have reported a placebo response rate ranging from 9% to 64% \[[@pone.0235961.ref038]--[@pone.0235961.ref040]\]. Along with Onabotulinum toxin A and PTNS, SNM has been a breakthrough in the treatment of refractory OAB and offers several advantages. A meta-analysis of 19 original studies, found Onabotulinum toxin A to be superior to placebo in reducing the episodes of urinary incontinence in patients with OAB \[[@pone.0235961.ref041]\]. However, intra-detrusor injection of Onabotulinum toxin A increases the risk of UTI and urinary retention necessitating clean intermittent catheterization (CIC).

PTNS is an effective neuromodulation treatment for OAB. The landmark study by Peters KM et al. demonstrated a level I evidence of its safety and efficacy in a multicenter, randomized, double-blind, sham controlled trial through 12 weeks of therapy \[[@pone.0235961.ref042]\]. However, with PTNS, patient compliance is a challenge since patients have to present weekly for in-office treatment, and it takes on an average more than 6 weeks for the patients to start experiencing improvement. Recently, MacDiarmid S et al. demonstrated the feasibility of an implantable nickel-sized tibial nerve stimulator in the treatment of OAB with a 71% reduction in the episodes of UUI, 70% response rate (more than 50% decrease in reported episodes of UUI) and 72% improvement in quality of life \[[@pone.0235961.ref043]\].

SNM overcomes the issues of UTI, urinary retention, CIC and poor compliance. However, SMN has its owns challenges that need to be addressed in the future including the need for two-staged procedures with at least one being under general anesthesia. Moreover, the implantable lead can cause complications of migration and prevent MRI use. Whether the use of SNM can lead to long-term cost reduction remains to be investigated. Future studies should also investigate therapies that are more cost-effective, can be used in-office, are less invasive without the need for general anesthesia, and are leadless.

We acknowledge limitations of our study. Despite conscious effort to monitor and control for them, this study may have been affected by biases inherent in retrospective cohort studies. The definition of primary outcome was based on the subjective assessment of patient\'s response by the physician without any use of objective measures such as voiding diaries, making our study susceptible to measurement bias. The sample size of 55 patients is not adequate to investigate various factors that might be associated with medium-term SNM outcomes. An absence of male subjects coupled with the fact that this study was conducted at a single institution limits the study's generalizability. As a result, additional studies from other centers and with larger sample sizes are needed to validate our findings. The strengths of this study include a homogeneous patient population with refractory OAB, relatively long median follow-up of approximately 3 years and a consecutive case series of all eligible patients during a specific time period thereby minimizing the possibility of selection bias.

Conclusion {#sec012}
==========

The success rate of SNM is 75% with a complication rate of 14.5% after a median follow-up of \~3 years. This study suggests medium-term efficacy and safety but a high re-operation rate of SNM in patients with refractory OAB. Future studies with larger sample sizes are needed to confirm these findings.
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Reviewer \#1: No

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

\*\*\*\*\*\*\*\*\*\*

5\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: 1. the subjective assessment of the patients by the physician : What was the relative score\\\\scale of the varios symptoms-frequency, urgency and UUI (how was the \>50% improvment calculated)before, immediately at the end of the test period as compared to that at the follow up. Was there a change in the symptomatic expression?

2\. The above information may enable to remove the column \"primary SNM indication: in table 1.

3\. Since there are no significant factors predicting the success rate, Table 2 can be removed leaving only the reported results in writting.

4\. Complications: Pain (3) and probably decrease device efficacy(5) should be consider as complication thus raising the complication rate to 13\\\\55=23.6%

Reviewer \#2: The authors present a retrospective analysis of the efficacy of SNM in 66 consecutively managed OAB cases with excellent results of improvement in pad use in about ¾ cases over a medium-term follow-up period. There is a moderately high SNM revision rate. Analysis did not reveal factors predictive of efficacy.

I have several caveats

1\. Expand a little on the specialist groups in society affected by OAB and expand on the economic community burden in investigation and management.

2\. The authors need to separate the reported incidence of occasional incontinence in women which in some studies is exceptionally high. i.e. to clarify a little their definitions in the introduction.

3\. The inclusion of bladder augmentation and urinary diversion is a bit extreme and should be removed in my view.

4\. Can they briefly elaborate on the proposed mechanisms of SNM in OAB?

5\. Comments on funding at the end of the discussion should be placed in a funding/financial disclosure statement and not at this point.

6\. Do we know anything about the clinical examination of these cases? Cystocele, rectocele, vault prolapse etc? I appreciate that these findings had no effect on efficacy.

7\. The authors discuss MRI compatible implantation..they could expand on some of the rechargeable devices which have been introduced for SNM with a conditional safety for full body MRI (e.g. De Wachter et al 2019) although it is accepted that these are less a requirement for some OAB cases and more for those cases needing high battery life. At any rate there can be a little extra discussion here.

8\. I would expand in the discussion on the proposed mechanisms of action of SNM in OAB (see above). I would also extend the level of sophistication of the discussion to expand on alternatives with comparison and consideration of their role e.g. PTNS, Transcutaneous TNS, peripheral implantables, transvaginal electrostimulation.

9\. Some comment needs to be made regarding the placebo effect and its comparison with other forms of stimulation e.g. the SuMit Trial and others...these need to be referenced in my opinion

Overall, I enjoyed this well written article. The data are limited but impressive and the article is short and punchy with a good design. I have added some caveats to consider in a revision of this useful manuscript.

I appreciate the opportunity of reviewing this interesting article

\*\*\*\*\*\*\*\*\*\*

6\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#2: Yes: Andrews P Zbar

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0235961.r002

Author response to Decision Letter 0

10 Feb 2020

Additional Editor Comments (if provided):

I acted as a reviewer for this manuscript as well as the Academic Editor. I would recommend that the paper be considered after revision with several caveats suggested by the two senior reviewers with experience in SNM technology and implantation. Recommended to alter the discussion and introduction to expand on the methods of efficacy in SNM for OAB and on comparative clinical alternatives along with an expansion on the importance of the placebo effect. The authors are congratulated on an impressive set of results in the medium-term in a well written style. I would also suggest that the follow-up is medium and not long-term.

MANY THANKS FOR YOUR VALUABLE FEEDBACK. WE HAVE ADDRESSED THE REVIEWERS' COMMENTS IN THE REVISED MANUSCRIPT (PLEASE SEE OUR RESPONSES BELOW). WE HAVE ALSO CHANGED THE FOLLOW-UP DURATION FROM LONG-TERM TO MEDIUM-TERM THROUGHOUT THE MANUSCRIPT (WHERE APPLICABLE).

Journal Requirements:

When submitting your revision, we need you to address these additional requirements:

1\. Please ensure that your manuscript meets PLOS ONE\'s style requirements, including those for file naming. The PLOS ONE style templates can be found at <http://www.plosone.org/attachments/PLOSOne_formatting_sample_main_body.pdf> and <http://www.plosone.org/attachments/PLOSOne_formatting_sample_title_authors_affiliations.pdf>

THANK YOU. WE HAVE DONE THE NEEDFUL.

2\. We noticed you have some minor occurrence(s) of overlapping text with the following previous publication(s), which needs to be addressed:

<https://doi.org/10.1007/s00192-017-3546-6>

In your revision ensure you cite all your sources (including your own works), and quote or rephrase any duplicated text outside the Methods section. Further consideration is dependent on these concerns being addressed.

THANK YOU FOR POINTING THIS OUT. AS ADVISED, WE HAVE REPHRASED THE OVERLAPPING TEXT IN OUR REVISED MANUSCRIPT.

3\. Thank you for stating the following in the Financial Disclosure section:

\"The authors received no specific funding for this work.\"

We note that one or more of the authors are employed by a commercial company: \'Clin-Science Research Consulting\'.

Please provide an amended Funding Statement declaring this commercial affiliation, as well as a statement regarding the Role of Funders in your study. If the funding organization did not play a role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript and only provided financial support in the form of authors\' salaries and/or research materials, please review your statements relating to the author contributions, and ensure you have specifically and accurately indicated the role(s) that these authors had in your study. You can update author roles in the Author Contributions section of the online submission form.

AD ADVISED, WE HAVE DECLARED THE COMMERCIAL AFFILIATION (CLIN-SCIENCE RESEARCH CONSULTING) FOR THE SECOND AUTHOR. THE AUTHOR CONTRIBUTION SECTION HAS ALSO BEEN UPDATED.

Please also include the following statement within your amended Funding Statement.

"The funder provided support in the form of salaries for authors \[insert relevant initials\], but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the 'author contributions' section."

If your commercial affiliation did play a role in your study, please state and explain this role within your updated Funding Statement.

AS SUGGESTED, WE HAVE NOW INCLUDED THE AMENDED FUNDING STATEMENT IN THE COVER LETTER ACCOMPANYING THE REVISED MANUSCRIPT.

Please also provide an updated Competing Interests Statement declaring this commercial affiliation along with any other relevant declarations relating to employment, consultancy, patents, products in development, or marketed products, etc.

Within your Competing Interests Statement, please confirm that this commercial affiliation does not alter your adherence to all PLOS ONE policies on sharing data and materials by including the following statement: \"This does not alter our adherence to PLOS ONE policies on sharing data and materials." (as detailed online in our guide for authors <http://journals.plos.org/plosone/s/competing-interests>) . If this adherence statement is not accurate and there are restrictions on sharing of data and/or materials, please state these. Please note that we cannot proceed with consideration of your article until this information has been declared.

AS ADVISED, WE HAVE CONFIRMED IN THE COVER LETTER THAT THE COMMERCIAL AFFILIATION DOES NOT ALTER OUR ADHERENCE TO PLOS ONE POLICIES ON SHARING DATA AND MATERIALS.

\* Please include both an updated Funding Statement and Competing Interests Statement in your cover letter. We will change the online submission form on your behalf.

Please know it is PLOS ONE policy for corresponding authors to declare, on behalf of all authors, all potential competing interests for the purposes of transparency. PLOS defines a competing interest as anything that interferes with, or could reasonably be perceived as interfering with, the full and objective presentation, peer review, editorial decision-making, or publication of research or non-research articles submitted to one of the journals. Competing interests can be financial or non-financial, professional, or personal. Competing interests can arise in relationship to an organization or another person. Please follow this link to our website for more details on competing interests: <http://journals.plos.org/plosone/s/competing-interests>

AS ADVISED, WE HAVE INCLUDED BOTH AN UPDATED FUNDING STATEMENT AND COMPETING INTERESTS STATEMENT IN OUR COVER LETTER. WE WOULD BE GRATEFUL IF YOU COULD PLEASE UPDATE THE ONLINE SUBMISSION FORM ON OUR BEHALF. THANK YOU.

Review Comments to the Author

Reviewer \#1: 1. The subjective assessment of the patients by the physician : What was the relative score\\\\scale of the various symptoms-frequency, urgency and UUI (how was the \>50% improvement calculated) before, immediately at the end of the test period as compared to that at the follow up. Was there a change in the symptomatic expression?

THANK FOR THIS QUERY. SUCCESS WAS DEFINED AS \>=50% IMPROVEMENT IN ANY CLINICAL PARAMETER AT THE LAST FOLLOW-UP BASED ON THE SUBJECTIVE ASSESSMENT OF PATIENT'S RESPONSE BY THE PHYSICIAN AS MENTIONED IN THE CLINICAL NOTE. IN OTHER WORDS, SUCCESS WAS CONSIDERED IF THE NUMBER OF URGENCY, FREQUENCY OR UUI EPISODES DROPPED BY HALF OR MORE, AS ASSESSED BY THE PHYSICIAN BASED ON PATIENT'S RESPONSE.

THE ABOVE HAS BEEN CLARIFIED IN THE METHODS SECTION OF THE REVISED MANUSCRIPT.

2\. The above information may enable to remove the column \"primary SNM indication: in table 1.

THANK YOU FOR THIS SUGGESTION. HOWEVER, WE WOULD LIKE TO REQUEST RETAINING THIS COLUMN IN THE TABLE BECAUSE IT DESCRIBES THAT ONLY 3 PATIENTS HAD URGENCY-FREQUENCY SYMPTOMS WITH NO INCONTINENCE (I.E. DRY OAB), WHEREAS 63 HAD URGENCY INCONTINENCE (I.E. WET OAB). OUT OF THE 63 WET OAB PATIENTS, 35 HAD MIXED URINARY INCONTINENCE WITH URGENCY PREDOMINANCE AND 28 HAD URGENCY URINARY INCONTINENCE.

3\. Since there are no significant factors predicting the success rate, Table 2 can be removed leaving only the reported results in writing.

WE UNDERSTAND THAT NONE OF THE EVALUATED FACTORS WERE SIGNIFICANT IN PREDICTING THE SUCCESS, HOWEVER WE WOULD STILL REQUEST TO RETAIN TABLE 2 IN THE MANUSCRIPT, BECAUSE THE TABLE PROVIDES THE PARAMETER ESTIMATES (OR ODDS RATIOS) FOR DIFFERENT RISK FACTORS WHICH MIGHT BE HELPFUL FOR OTHER RESEARCHERS IN THEIR FUTURE INVESTIGATIONS.

4\. Complications: Pain (3) and probably decrease device efficacy (5) should be consider as complication thus raising the complication rate to 13\\\\55=23.6%

AS SUGGESTED, WE HAVE INCLUDED PAIN AS A COMPLICATION, SO THE NEW COMPLICATION RATE IS NOW 8/55=14.5%. THIS HAS BEEN UPDATED THROUGHOUT THE MANUSCRIPT.

DECREASED DEVICE EFFICACY (N=5) WAS NOT A DIRECT COMPLICATION OF THE IMPLANT PROCEDURE AND CAN PARTIALLY BE CONTRIBUTED BY A PHYSIOLOGIC EFFECT DUE TO HABITUATION OF THE NERVOUS SYSTEM. AS A RESULT, WE HAVE NOT CONSIDERED DECREASED DEVICE EFFICACY AS A COMPLICATION.

Reviewer \#2: The authors present a retrospective analysis of the efficacy of SNM in 66 consecutively managed OAB cases with excellent results of improvement in pad use in about ¾ cases over a medium-term follow-up period. There is a moderately high SNM revision rate. Analysis did not reveal factors predictive of efficacy.

I have several caveats:

1\. Expand a little on the specialist groups in society affected by OAB and expand on the economic community burden in investigation and management.

AS SUGGESTED, THIS DESCRIPTION HAS NOW BEEN ADDED IN THE INTRODUCTION SECTION OF THE REVISED MANUSCRIPT. APPROPRIATE REFERENCES HAVE ALSO BEEN ADDED.

2\. The authors need to separate the reported incidence of occasional incontinence in women which in some studies is exceptionally high. i.e. to clarify a little their definitions in the introduction.

AS ADVISED, WE HAVE ADDED MORE CLARITY ON THE DIFFERENT TYPES OF URINARY INCONTINENCE IN THE INTRODUCTION SECTION. PLEASE NOTE THAT OUR STUDY WAS FOCUSED ON PATIENTS WITH REFRACTORY OAB.

3\. The inclusion of bladder augmentation and urinary diversion is a bit extreme and should be removed in my view.

AS ADVISED, WE HAVE REMOVED THESE TREATMENT OPTIONS FROM THE INTRODUCTION.

4\. Can they briefly elaborate on the proposed mechanisms of SNM in OAB?

AS ADVISED, THIS HAS NOW BEEN DONE IN THE INTRODUCTION SECTION OF THE REVISED MANUSCRIPT. APPROPRIATE REFERENCES HAVE ALSO BEEN ADDED.

5\. Comments on funding at the end of the discussion should be placed in a funding/financial disclosure statement and not at this point.

AS SUGGESTED, WE HAVE REMOVED THE FUNDING STATEMENT FROM THE DISCUSSION SECTION. AS A PART OF THE JOURNAL REQUIREMENT, WE HAVE NOW INCLUDED THE AMENDED FUNDING STATEMENT IN THE COVER LETTER ACCOMPANYING THE REVISED MANUSCRIPT.

6\. Do we know anything about the clinical examination of these cases? Cystocele, rectocele, vault prolapse etc? I appreciate that these findings had no effect on efficacy.

THE FOLLOWING CONCOMITANT CONDITIONS WERE EVALUATED: VOIDING DYSFUNCTION, STRESS URINARY INCONTINENCE \[SUI\], PELVIC ORGAN PROLAPSE, RECURRENT URINARY TRACT INFECTION \[UTI\], AND FECAL INCONTINENCE. WITHIN THE CATEGORY OF PELVIC ORGAN PROLAPSE, THE FOLLOWING CONDITIONS WERE INCLUDED: CYSTOCELE, ENTEROCELE, RECTOCELE, UTERINE PROLAPSE AND VAGINAL VAULT PROLAPSE. THIS HAS NOW BEEN CLARIFIED IN THE METHODS SECTION OF THE REVISED MANUSCRIPT.

7\. The authors discuss MRI compatible implantation...they could expand on some of the rechargeable devices which have been introduced for SNM with a conditional safety for full body MRI (e.g. De Wachter et al 2019) although it is accepted that these are less a requirement for some OAB cases and more for those cases needing high battery life. At any rate there can be a little extra discussion here.

AS ADVISED, WE HAVE NOW INCLUDED SOME DISCUSSION AROUND THIS NEW DEVICE IN THE REVISED MANUSCRIPT. APPROPRIATE REFERENCE HAS ALSO BEEN ADDED.

8\. I would expand in the discussion on the proposed mechanisms of action of SNM in OAB (see above). I would also extend the level of sophistication of the discussion to expand on alternatives with comparison and consideration of their role e.g. PTNS, Transcutaneous TNS, peripheral implantables, transvaginal electrostimulation.

AS ADVISED, WE HAVE NOW EXPANDED THE DISCUSSION ON THE ROLE OF SOME TREATMENT ALTERNATIVES FOR OAB (ALONG WITH THE SUPPORTING REFERENCES).

9\. Some comment needs to be made regarding the placebo effect and its comparison with other forms of stimulation e.g. the SuMit Trial and others...these need to be referenced in my opinion

AS ADVISED, A DISCUSSION ON PACEBO EFFECT (ALONG WITH SUMIT TRIAL AND OTHER RELEVANT STUDIES) HAS BEEN INCLUDED IN THE REVISED MANUSCRIPT.

Overall, I enjoyed this well written article. The data are limited but impressive and the article is short and punchy with a good design. I have added some caveats to consider in a revision of this useful manuscript.

I appreciate the opportunity of reviewing this interesting article.

THANK YOU FOR ALL YOUR CONSTRUCTIVE FEEDBACK IN HELPING US IMPROVE OUR MANUSCRIPT.
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Medium-term outcomes of sacral neuromodulation in patients with refractory overactive bladder: a retrospective single-institution study

PLOS ONE

Dear Dr. Gupta,

Thank you for submitting your manuscript to PLOS ONE. After careful consideration, we feel that it has merit but does not fully meet PLOS ONE's publication criteria as it currently stands. Therefore, we invite you to submit a revised version of the manuscript that addresses the points raised during the review process.

==============================

ACADEMIC EDITOR: I take this opportunity to point out to you that the origin of \'overactive bladder\' in the ICS is not overactive bladder, but \'overactive bladder syndrome\' and ask you to correct this. You have also introduced \'voiding dysfunction\' and \'SUI\' in the manuscript. Your manuscript does however not state that it has been established other than on the basis of symptoms. That is why I ask you to think about replacing with \'voiding symptoms\' and \'symptoms of stress urinary incontinence\'. You also seem, as a reaction to earlier reviews, to be concerned about the numbers of patients with the syndrome and the costs involved, I agree with that. Can you include in the discussion how your approach - with an expensive intervention, without any kind of objective diagnosis - can lead to a reduction in costs and whether, for example, how medical self-regulation can be used to reduce costs?

Please ensure that your decision is justified on PLOS ONE's [publication criteria](https://journals.plos.org/plosone/s/criteria-for-publication) and not, for example, on novelty or perceived impact.

==============================

Please submit your revised manuscript by Jul 19 2020 11:59PM. If you will need more time than this to complete your revisions, please reply to this message or contact the journal office at <plosone@plos.org>. When you\'re ready to submit your revision, log on to <https://www.editorialmanager.com/pone/> and select the \'Submissions Needing Revision\' folder to locate your manuscript file.

Please include the following items when submitting your revised manuscript:

A rebuttal letter that responds to each point raised by the academic editor and reviewer(s). You should upload this letter as a separate file labeled \'Response to Reviewers\'.A marked-up copy of your manuscript that highlights changes made to the original version. You should upload this as a separate file labeled \'Revised Manuscript with Track Changes\'.An unmarked version of your revised paper without tracked changes. You should upload this as a separate file labeled \'Manuscript\'.

If you would like to make changes to your financial disclosure, please include your updated statement in your cover letter. Guidelines for resubmitting your figure files are available below the reviewer comments at the end of this letter.

If applicable, we recommend that you deposit your laboratory protocols in protocols.io to enhance the reproducibility of your results. Protocols.io assigns your protocol its own identifier (DOI) so that it can be cited independently in the future. For instructions see: <http://journals.plos.org/plosone/s/submission-guidelines#loc-laboratory-protocols>

We look forward to receiving your revised manuscript.

Kind regards,

Peter F.W.M. Rosier, M.D. PhD

Academic Editor

PLOS ONE

\[Note: HTML markup is below. Please do not edit.\]

Reviewers\' comments:

Reviewer\'s Responses to Questions

**Comments to the Author**

1\. If the authors have adequately addressed your comments raised in a previous round of review and you feel that this manuscript is now acceptable for publication, you may indicate that here to bypass the "Comments to the Author" section, enter your conflict of interest statement in the "Confidential to Editor" section, and submit your \"Accept\" recommendation.

Reviewer \#1: All comments have been addressed

Reviewer \#3: (No Response)

\*\*\*\*\*\*\*\*\*\*

2\. Is the manuscript technically sound, and do the data support the conclusions?

The manuscript must describe a technically sound piece of scientific research with data that supports the conclusions. Experiments must have been conducted rigorously, with appropriate controls, replication, and sample sizes. The conclusions must be drawn appropriately based on the data presented.

Reviewer \#1: Yes

Reviewer \#3: Partly

\*\*\*\*\*\*\*\*\*\*

3\. Has the statistical analysis been performed appropriately and rigorously?

Reviewer \#1: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

4\. Have the authors made all data underlying the findings in their manuscript fully available?

The [PLOS Data policy](http://www.plosone.org/static/policies.action#sharing) requires authors to make all data underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data---e.g. participant privacy or use of data from a third party---those must be specified.

Reviewer \#1: Yes

Reviewer \#3: No

\*\*\*\*\*\*\*\*\*\*

5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#3: Yes

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)

Reviewer \#1: The authors have answered the reviewers comments. It is a detailed though retrospective work which reasures physicians as well as patients with ORB to use SNM as a sound therapeutic option. The work is now eligible for publication

Reviewer \#3: The authors have a nice retrospective case series with 66 patients having a median follow up of 32 months. This is not long-term but they have had excellent outcomes with 74.5% reporting \>50% improvement.

They report 27.3% explant at 24 months. This is high, even for 32 months' follow up, when compared to 19.1% by Siegel et al who report 5 year outcomes for a multicenter RCT (INSITE)\[1\]. IT should be clarified by the authors how many of these 27% got re-implanted when appropriate and for which reasons. The 5 explanted for loss of efficacy should be specifically stated for the reader if they were counted as therapeutic failures.

The authors make the statement that medium and long term outcomes for safety and efficacy for SNM are limited. This is not really supported by the literature \[1-9\] with outcomes as long as 17 years for tined lead removal \[6\] and one manuscript dating back to 2010 with 5 year average outcomes \[5\].

PLOS One requires that all data be made available to the reader, it is not part of the submitted manuscript and as far as I can tell, not submitted as supporting information. This should be remedied as a requirement of the journal.

Table 1, it is a little confusing that the authors report mean followed by a comma, then median results. This would normally be reported as 2 separate columns and I suspect that will be an easy change and make it easier for the reader to understand

Table 2, for what it's worth I agree with the authors' response to reviewer \#1 that although no factors were significant predictors, calling attention to this with a table may be helpful to some readers. I think publishing negative results can be nearly as helpful as positive ones in some cases.

Overall this appears to be a community based medium-term case series and may be of interest to some readers for that reason.

\[1\] Siegel S, Noblett K, Mangel J, Bennett J, Griebling TL, Sutherland SE, et al. Five-Year Followup Results of a Prospective, Multicenter Study of Patients with Overactive Bladder Treated with Sacral Neuromodulation. J Urol. 2018;199:229-36.

\[2\] Amundsen CL, Komesu YM, Chermansky C, Gregory WT, Myers DL, Honeycutt EF, et al. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial. Eur Urol. 2018;74:66-73.

\[3\] Blok B, Van Kerrebroeck P, de Wachter S, Ruffion A, Van der Aa F, Perrouin-Verbe MA, et al. Two-year safety and efficacy outcomes for the treatment of overactive bladder using a long-lived rechargeable sacral neuromodulation system. Neurourol Urodyn. 2020.

\[4\] Ismail S, Chartier-Kastler E, Perrouin-Verbe MA, Rose-Dite-Modestine J, Denys P, Phe V. Long-Term Functional Outcomes of S3 Sacral Neuromodulation for the Treatment of Idiopathic Overactive Bladder. Neuromodulation. 2017;20:825-9.

\[5\] Marinkovic SP, Gillen LM, Marinkovic CM. Minimum 6-year outcomes for interstitial cystitis treated with sacral neuromodulation. Int Urogynecol J. 2011;22:407-12.

\[6\] Powell CR, Kreder KJ. Long-term outcomes of urgency-frequency syndrome due to painful bladder syndrome treated with sacral neuromodulation and analysis of failures. J Urol. 2010;183:173-6.

\[7\] Rueb JJ, Pizarro-Berdichevsky J, Goldman HB. 17-Year Single Center Retrospective Review of Rate, Risk Factors, and Outcomes of Lead Breakage during Sacral Neuromodulation Lead Removal. J Urol. 2020:101097JU0000000000000740.

\[8\] Yazdany T, Bhatia N, Nguyen J. Determining outcomes, adverse events, and predictors of success after sacral neuromodulation for lower urinary disorders in women. Int Urogynecol J. 2011;22:1549-54.

\[9\] Zegrea A, Kirss J, Pinta T, Rautio T, Varpe P, Kairaluoma M, et al. Outcomes of sacral neuromodulation for chronic pelvic pain: a Finnish national multicenter study. Tech Coloproctol. 2020;24:215-20.

\*\*\*\*\*\*\*\*\*\*

7\. PLOS authors have the option to publish the peer review history of their article ([what does this mean?](https://journals.plos.org/plosone/s/editorial-and-peer-review-process#loc-peer-review-history)). If published, this will include your full peer review and any attached files.

If you choose "no", your identity will remain anonymous but your review may still be made public.

**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).

Reviewer \#1: No

Reviewer \#3: Yes: CR Powell, MD

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email PLOS at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0235961.r004
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ATTACHED BELOW, FOR YOUR PERUSAL, IS A DETAILED DESCRIPTION (HIGHLIGHTED IN RED AND CAPS) OF HOW WE'VE ADDRESSED THE REVIEWERS' COMMENTS.

Additional Editor Comments:

I take this opportunity to point out to you that the origin of \'overactive bladder\' in the ICS is not overactive bladder, but \'overactive bladder syndrome\' and ask you to correct this.

THANKS FOR POINTING THIS OUT. AS SUGGESTED, WE HAVE MADE THIS CORRECTION IN THE REVISED MANUSCRIPT (BOTH IN THE ABSTRACT AND THE MAIN TEXT).

You have also introduced \'voiding dysfunction\' and \'SUI\' in the manuscript. Your manuscript does however not state that it has been established other than on the basis of symptoms. That is why I ask you to think about replacing with \'voiding symptoms\' and \'symptoms of stress urinary incontinence\'.

WE HAVE MADE THE SUGGESTED REPLACEMENTS THROUGHOUT THE MANUSCRIPT.

You also seem, as a reaction to earlier reviews, to be concerned about the numbers of patients with the syndrome and the costs involved, I agree with that. Can you include in the discussion how your approach - with an expensive intervention, without any kind of objective diagnosis - can lead to a reduction in costs and whether, for example, how medical self-regulation can be used to reduce costs?

THE FOCUS OF OUR PAPER WAS NOT ON THE COST-BENEFIT ANALYSIS OF SNM, HOWEVER, BASED ON YOUR SUGGESTION, WE HAVE INCLUDED A GENERAL POINT IN THE DISCUSSION THAT THE LONG-TERM COST BENEFITS OF SNM NEED TO BE INVESTIGATED IN FUTURE STUDIES.

Review Comments to the Author

Reviewer \#1: The authors have answered the reviewers' comments. It is a detailed though retrospective work which reassures physicians as well as patients with ORB to use SNM as a sound therapeutic option. The work is now eligible for publication.

MANY THANKS ONCE AGAIN FOR YOUR VALUABLE FEEDBACK.

Reviewer \#3: The authors have a nice retrospective case series with 66 patients having a median follow up of 32 months. This is not long-term but they have had excellent outcomes with 74.5% reporting \>50% improvement.

THANK YOU.

They report 27.3% explant at 24 months. This is high, even for 32 months' follow up, when compared to 19.1% by Siegel et al who report 5 year outcomes for a multicenter RCT (INSITE)\[1\]. It should be clarified by the authors how many of these 27% got re-implanted when appropriate and for which reasons. NONE OF THESE 27% (N=15) PATIENTS GOT RE-IMPLANTED. THIS HAS BEEN CLARIFIED IN THE RESULTS SECTION OF THE REVISED MANUSCRIPT. The 5 explanted for loss of efficacy should be specifically stated for the reader if they were counted as therapeutic failures. YES, THEY WERE CONSIDERED THERAPEUTIC FAILURES. THIS HAS BEEN CLARIFIED IN THE RESULTS SECTION OF THE REVISED MANUSCRIPT.

The authors make the statement that medium and long term outcomes for safety and efficacy for SNM are limited. This is not really supported by the literature \[1-9\] with outcomes as long as 17 years for tined lead removal \[6\] and one manuscript dating back to 2010 with 5 year average outcomes \[5\].
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PLOS One requires that all data be made available to the reader, it is not part of the submitted manuscript and as far as I can tell, not submitted as supporting information. This should be remedied as a requirement of the journal.

THANKS FOR RAISING THIS POINT. PLEASE NOTE THAT AS PER THE JOURNAL REQUIREMENTS, WE HAVE INCLUDED THE FOLLOWING IN OUR COVER LETTER TO THE EDITOR.

We would like to confirm that the data underlying the findings in our study cannot be made publicly available due to ethical and legal restrictions. The original data contains potentially identifying or sensitive patient information. This restriction has been imposed by the Allen College Institutional Review Board (ACIRB). However, a copy of the de-identified dataset underlying the analyses reported in this paper is available to all interested researchers upon request to the ACIRB (contact person is Lisa Brodersen who can be reached at <Lisa.Brodersen@allencollege.edu> or 319-226-2000).
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